{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:16:28Z","timestamp":1793394988724,"version":"4.5.0"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.phrs.2022.106552","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T11:37:40Z","timestamp":1668685060000},"page":"106552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":273,"special_numbering":"C","title":["Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update"],"prefix":"10.1016","volume":"187","author":[{"suffix":"Jr","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2022.106552_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases \u2013 the major drug targets of the twenty-first century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2022.106552_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2022.106552_bib4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2022.106552_bib5","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.tips.2019.09.002","article-title":"The landscape of atypical and eukaryotic protein kinases","volume":"40","author":"Kanev","year":"2019","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.phrs.2022.106552_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23040908","article-title":"PKIDB: a curated, annotated and updated database of protein kinase inhibitors in clinical trials","volume":"23","author":"Carles","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2022.106552_bib7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/med.21409","article-title":"Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview","volume":"37","author":"Fischer","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.phrs.2022.106552_bib8","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2022.106552_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105579","article-title":"Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies","volume":"168","author":"Roskoski","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105463","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106037","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update","volume":"175","author":"Roskoski","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib14","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1021\/acs.jmedchem.5b01273","article-title":"AXL inhibitors in cancer: a medicinal chemistry perspective","volume":"59","author":"Myers","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2022.106552_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2022.106552_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105422","article-title":"Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2022.106552_bib18","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tibs.2015.09.002","article-title":"Dynamics-driven allostery in protein kinases","volume":"40","author":"Kornev","year":"2015","journal-title":"Trends. Biochem. Sci."},{"key":"10.1016\/j.phrs.2022.106552_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100746","article-title":"From structure to the dynamic regulation of a molecular switch: A journey over 3 decades","volume":"296","author":"Taylor","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2022.106552_bib20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","article-title":"Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105660","article-title":"Hydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes","volume":"169","author":"Roskoski","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib22","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","article-title":"Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification","volume":"9","author":"Hanks","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2022.106552_bib23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/pro.5560030203","article-title":"cAMP-dependent protein kinase: crystallographic insights into substrate recognition and phosphotransfer","volume":"3","author":"Madhusudan","year":"1994","journal-title":"Protein Sci."},{"key":"10.1016\/j.phrs.2022.106552_bib24","doi-asserted-by":"crossref","first-page":"15733","DOI":"10.1021\/bi971438n","article-title":"Participation of ADP dissociation in the rate-determining step in cAMP-dependent protein kinase","volume":"36","author":"Zhou","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2022.106552_bib25","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bioorg.2011.07.004","article-title":"Protein kinase biochemistry and drug discovery","volume":"39","author":"Schwartz","year":"2011","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2022.106552_bib26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.bbapap.2009.10.017","article-title":"Defining the conserved internal architecture of a protein kinase","volume":"1804","author":"Kornev","year":"2010","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.phrs.2022.106552_bib27","doi-asserted-by":"crossref","first-page":"6818","DOI":"10.1073\/pnas.1814279116","article-title":"Defining a new nomenclature for the structures of active and inactive kinases","volume":"116","author":"Modi","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2022.106552_bib28","doi-asserted-by":"crossref","first-page":"D654","DOI":"10.1093\/nar\/gkab920","article-title":"Kincore: a web resource for structural classification of protein kinases and their inhibitors","volume":"50","author":"Modi","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2022.106552_bib29","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2022.106552_bib30","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2022.106552_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2022.106552_bib32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib34","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib35","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/17460441.2013.813015","article-title":"The preclinical profile of crizotinib in the treatment of non-small cell lung cancer and other neoplastic disorders","volume":"8","author":"Roskoski","year":"2013","journal-title":"Expert Opin. Drug Dis."},{"key":"10.1016\/j.phrs.2022.106552_bib36","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.phrs.2014.06.001","article-title":"ErbB\/HER protein-tyrosine kinases: structure and small molecule inhibitors","volume":"87","author":"Roskoski","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib38","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.01.021","article-title":"The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders","volume":"129","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2018.04.020","article-title":"The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders","volume":"133","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib43","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","article-title":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","volume":"121","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104725","article-title":"The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias","volume":"155","author":"Roskoski","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106156","article-title":"Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia","volume":"178","author":"Roskoski","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib47","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106362","article-title":"Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders","volume":"183","author":"Roskoski","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib49","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2016.09.011","article-title":"Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms","volume":"113","author":"Roskoski","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib51","series-title":"Reference Module in life Sciences","first-page":"1","article-title":"Src family tyrosine kinases","author":"Frame","year":"2017"},{"key":"10.1016\/j.phrs.2022.106552_bib52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bbrc.2011.11.145","article-title":"MEK1\/2 dual-specificity protein kinases: structure and regulation","volume":"417","author":"Roskoski","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2022.106552_bib53","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","article-title":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib54","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.phrs.2016.03.012","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"107","author":"Roskoski","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib55","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib56","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2019.01.039","article-title":"Targeting ERK1\/2 protein-serine\/threonine kinases in human cancers","volume":"142","author":"Roskoski","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib57","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib58","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbrc.2010.07.092","article-title":"RAF protein-serine\/threonine kinases: structure and regulation","volume":"399","author":"Roskoski","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2022.106552_bib59","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0968-0896(98)00099-6","article-title":"A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src","volume":"6","author":"Liu","year":"1998","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2022.106552_bib60","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu Rev. Biochem."},{"key":"10.1016\/j.phrs.2022.106552_bib61","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.chembiol.2018.05.002","article-title":"Redefining the protein kinase conformational space with machine learning","volume":"25","author":"Ung","year":"2018","journal-title":"Cell Chem. Biol."},{"issue":"D1","key":"10.1016\/j.phrs.2022.106552_bib62","doi-asserted-by":"crossref","first-page":"D552","DOI":"10.1093\/nar\/gkaa945","article-title":"KinaseMD: kinase mutations and drug response database","volume":"49","author":"Hu","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2022.106552_bib63","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1021\/jm901443h","article-title":"Through the \"gatekeeper door\": exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2022.106552_bib64","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1039\/C2MD20180A","article-title":"Approaches to discover non-ATP site inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.phrs.2022.106552_bib65","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.2174\/138161212800672813","article-title":"New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2022.106552_bib66","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2022.106552_bib67","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space","volume":"57","author":"van Linden","year":"2014","journal-title":"J. Med. Chem."},{"issue":"D1","key":"10.1016\/j.phrs.2022.106552_bib68","doi-asserted-by":"crossref","first-page":"D365","DOI":"10.1093\/nar\/gkv1082","article-title":"KLIFS: a structural kinase-ligand interaction database","volume":"44","author":"Kooistra","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2022.106552_bib69","first-page":"gkaa895","article-title":"KLIFS: an overhaul after the first 5 years of supporting kinase research","author":"Kanev","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2022.106552_bib70","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1021\/acschembio.9b00476","article-title":"Surprising non-additivity of methyl groups in drug-kinase interaction","volume":"14","author":"Wienen-Schmidt","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2022.106552_bib71","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2174\/1568026617666170224121313","article-title":"Structure-based virtual screening approaches in kinase-directed drug discovery","volume":"17","author":"Bajusz","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.phrs.2022.106552_bib72","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.phrs.2022.106552_bib73","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2022.106552_bib74","article-title":"Janus Kinase inhibitors for the treatment of atopic dermatitis: focus on abrocitinib, baricitinib, and upadacitinib","volume":"11","author":"Nogueira","year":"2021","journal-title":"Dermatol. Pr. Concept"},{"key":"10.1016\/j.phrs.2022.106552_bib75","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.phrs.2022.106552_bib76","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1007\/s40265-021-01638-3","article-title":"Abrocitinib: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2022.106552_bib77","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cmdc.201800719","article-title":"TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor\u20051 (FGFR1) irreversible structure","volume":"14","author":"Kalyukina","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.phrs.2022.106552_bib78","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2022.106552_bib79","article-title":"FGFR2 inhibition in cholangiocarcinoma","author":"Vogel","year":"2022","journal-title":"Annu Rev. Med."},{"key":"10.1016\/j.phrs.2022.106552_bib80","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/ FGFR aberrations: A phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2022.106552_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib82","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.jmb.2013.03.018","article-title":"Polyproline-II helix in proteins: structure and function","volume":"425","author":"Adzhubei","year":"2013","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2022.106552_bib83","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.febslet.2012.04.054","article-title":"The language of SH2 domain interactions defines phosphotyrosine-mediated signal transduction","volume":"586","author":"Liu","year":"2012","journal-title":"FEBS Lett."},{"key":"10.1016\/j.phrs.2022.106552_bib84","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0968-0004(00)89103-3","article-title":"Recognition and specificity in protein tyrosine kinase-mediated signalling","volume":"20","author":"Songyang","year":"1995","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.phrs.2022.106552_bib85","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1280","article-title":"Regulation of the c-Abl and Bcr-Abl tyrosine kinases","volume":"5","author":"Hantschel","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2022.106552_bib86","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","article-title":"A myristoyl\/phosphotyrosine switch regulates c-Abl","volume":"112","author":"Hantschel","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2022.106552_bib87","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","article-title":"Structural basis for the autoinhibition of c-Abl tyrosine kinase","volume":"112","author":"Nagar","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2022.106552_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102247","article-title":"Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors","volume":"298","author":"Arter","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2022.106552_bib89","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chembiol.2010.12.013","article-title":"Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site","volume":"18","author":"Yang","year":"2011","journal-title":"Chem. Biol."},{"key":"10.1016\/j.phrs.2022.106552_bib90","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2022.106552_bib91","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-021-01662-3","article-title":"Asciminib: first approval","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2022.106552_bib92","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s40265-022-01718-y","article-title":"Pacritinib: First approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2022.106552_bib93","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/17474086.2022.2112565","article-title":"Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia","volume":"15","author":"Mascarenhas","year":"2022","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.phrs.2022.106552_bib94","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2022.106552_bib95","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","article-title":"Ligand efficiency: a useful metric for lead selection","volume":"9","author":"Hopkins","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2022.106552_bib96","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2022.106552_bib97","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11095-015-1779-y","article-title":"Thermodynamic proxies to compensate for biases in drug discovery methods","volume":"33","author":"Ekins","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib98","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","article-title":"The role of ligand efficiency metrics in drug discovery","volume":"13","author":"Hopkins","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2022.106552_bib99","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.addr.2016.01.018","article-title":"Molecular inflation, attrition, and the rule of five","volume":"101","author":"Leeson","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2022.106552_bib100","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2022.106552_bib101","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1008130001697","article-title":"Property distribution of drug-related chemical databases","volume":"14","author":"Oprea","year":"2000","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.phrs.2022.106552_bib102","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.1021\/acs.jmedchem.1c00416","article-title":"Target-based evaluation of \"drug-like\" properties and ligand efficiencies","volume":"64","author":"Leeson","year":"2021","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2022.106552_bib103","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.1021\/jm300967g","volume":"55","author":"Cui","year":"2012","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2022.106552_bib104","first-page":"3559","article-title":"The first general index of molecular complexity","volume":"1103","author":"Bertz","year":"1981","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2022.106552_bib105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1021\/ci00054a004","article-title":"Molecular complexity: a simplified formula adapted to individual atoms","volume":"27","author":"Hendrickson","year":"1987","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.phrs.2022.106552_bib106","doi-asserted-by":"crossref","first-page":"7206","DOI":"10.1021\/jm500515d","article-title":"Physicochemical descriptors of aromatic character and their use in drug discovery","volume":"57","author":"Ritchie","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2022.106552_bib107","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.drudis.2016.07.007","article-title":"Quality guidelines for oral drug candidates: dose, solubility and lipophilicity","volume":"21","author":"Bayliss","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2022.106552_bib108","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd.2018.52","article-title":"Unexplored therapeutic opportunities in the human genome","volume":"17","author":"Oprea","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2022.106552_bib109","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2022.106552_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104392","article-title":"The new entries in the therapeutic armamentarium: the small molecule JAK inhibitors","volume":"147","author":"Bechman","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib111","unstructured":"Bechman K., Galloway G.B., Winthrop K.L. Small-molecule protein kinase inhibitors and the risk of fungal infections. Curr Fungal Infect Rep. 10.1007\/s12281\u2013019-00350-w."},{"key":"10.1016\/j.phrs.2022.106552_bib112","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/ijms22020566","article-title":"The kinase chemogenomic set (KCGS): an open science resource for kinase vulnerability identification","volume":"22","author":"Wells","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2022.106552_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105412","article-title":"Posttranslational modifications as therapeutic targets for intestinal disorders","author":"Choo","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib114","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","article-title":"small molecule kinase inhibitor drugs (1995-2021): medical indication, pharmacology, and synthesis","volume":"65","author":"Ayala-Aguilera","year":"2022","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2022.106552_bib115","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1021\/acs.jmedchem.0c01511","article-title":"Small-molecule kinase inhibitors for the treatment of nononcologic diseases","volume":"64","author":"Xie","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2022.106552_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105806","article-title":"Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS","volume":"172","author":"Roskoski","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106552_bib117","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1038\/s41467-021-23165-1","article-title":"Crowdsourced mapping of unexplored target space of kinase inhibitors","volume":"12","author":"Cicho\u0144ska","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2022.106552_bib118","doi-asserted-by":"crossref","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","author":"Min","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.phrs.2022.106552_bib119","doi-asserted-by":"crossref","first-page":"13764","DOI":"10.1002\/anie.201914525","article-title":"New promise and opportunities for allosteric kinase inhibitors","volume":"59","author":"Lu","year":"2020","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"10.1016\/j.phrs.2022.106552_bib120","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.phrs.2022.106552_bib121","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/cncr.33933","article-title":"The cure of leukemia through the optimist's prism","volume":"128","author":"Kantarjian","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2022.106552_bib122","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","article-title":"Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.phrs.2022.106552_bib123","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","article-title":"Chronic myeloid leukemia","volume":"398","author":"Cortes","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2022.106552_bib124","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ajh.26550","article-title":"Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors","volume":"97","author":"Haddad","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.phrs.2022.106552_bib125","first-page":"240","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822004984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822004984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:39:30Z","timestamp":1760913570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822004984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":125,"alternative-id":["S1043661822004984"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106552","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106552","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106552"}}